These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 35953544)
1. A disturbed balance between blood complement protective factors (FH, ApoE) and common pathway effectors (C5a, TCC) in acute COVID-19 and during convalesce. Laudanski K; Okeke T; Siddiq K; Hajj J; Restrepo M; Gullipalli D; Song WC Sci Rep; 2022 Aug; 12(1):13658. PubMed ID: 35953544 [TBL] [Abstract][Full Text] [Related]
2. Immunological Signatures in Blood and Urine in 80 Individuals Hospitalized during the Initial Phase of COVID-19 Pandemic with Quantified Nicotine Exposure. Laudanski K; Mahmoud MA; Ahmed AS; Susztak K; Mathew A; Chen J Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612525 [TBL] [Abstract][Full Text] [Related]
3. A decline of protective apolipoprotein J and complement factor H concomitant with increase in C5a 3 months after cardiac surgery-Evidence of long-term complement perturbations. Laudanski K; Liu D; Gullipalli D; Song WC; Okeke T; Szeto WY Front Cardiovasc Med; 2022; 9():983617. PubMed ID: 36606279 [TBL] [Abstract][Full Text] [Related]
5. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308 [TBL] [Abstract][Full Text] [Related]
6. C5a anaphylatoxin as a product of complement activation up-regulates the complement inhibitory factor H in rat Kupffer cells. Schlaf G; Nitzki F; Heine I; Hardeland R; Schieferdecker HL; Götze O Eur J Immunol; 2004 Nov; 34(11):3257-66. PubMed ID: 15376195 [TBL] [Abstract][Full Text] [Related]
7. Complement activation predicts negative outcomes in COVID-19: The experience from Northen Italian patients. Meroni PL; Croci S; Lonati PA; Pregnolato F; Spaggiari L; Besutti G; Bonacini M; Ferrigno I; Rossi A; Hetland G; Hollan I; Cugno M; Tedesco F; Borghi MO; Salvarani C Autoimmun Rev; 2023 Jan; 22(1):103232. PubMed ID: 36414219 [TBL] [Abstract][Full Text] [Related]
8. Systemic Inflammation and Complement Activation Parameters Predict Clinical Outcome of Severe SARS-CoV-2 Infections. Huber S; Massri M; Grasse M; Fleischer V; Kellnerová S; Harpf V; Knabl L; Knabl L; Heiner T; Kummann M; Neurauter M; Rambach G; Speth C; Würzner R Viruses; 2021 Nov; 13(12):. PubMed ID: 34960645 [TBL] [Abstract][Full Text] [Related]
9. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19. Valenti L; Griffini S; Lamorte G; Grovetti E; Uceda Renteria SC; Malvestiti F; Scudeller L; Bandera A; Peyvandi F; Prati D; Meroni P; Cugno M J Autoimmun; 2021 Feb; 117():102595. PubMed ID: 33453462 [TBL] [Abstract][Full Text] [Related]
10. Detection of renal allograft rejection by complement components C5A and TCC in plasma and urine. Müller TF; Kraus M; Neumann C; Lange H J Lab Clin Med; 1997 Jan; 129(1):62-71. PubMed ID: 9011592 [TBL] [Abstract][Full Text] [Related]
12. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program. Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877 [TBL] [Abstract][Full Text] [Related]
13. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T; Trials; 2021 May; 22(1):343. PubMed ID: 34001215 [TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial. Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ Trials; 2021 May; 22(1):342. PubMed ID: 34001174 [TBL] [Abstract][Full Text] [Related]